| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Robin Spiller | Q42693271 |
| P2093 | author name string | Klara Garsed | |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | irritable bowel syndrome | Q838966 |
| P304 | page(s) | 1979-1988 | |
| P577 | publication date | 2009-05-07 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Postinfectious irritable bowel syndrome. | |
| P478 | volume | 136 |
| Q47160578 | A Novel Prebiotic Blend Product Prevents Irritable Bowel Syndrome in Mice by Improving Gut Microbiota and Modulating Immune Response |
| Q47934836 | A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. |
| Q48783040 | A case-control study of childhood trauma in the development of irritable bowel syndrome |
| Q36179468 | A gastroenterologist's guide to probiotics |
| Q36475488 | A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). |
| Q33795765 | A mixed methods feasibility study to evaluate the use of a low-intensity, nurse-delivered cognitive behavioural therapy for the treatment of irritable bowel syndrome |
| Q34237231 | A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea |
| Q34416297 | A role for the gut microbiota in IBS. |
| Q38920817 | ASSESSING THE SLEEP QUALITY AND DEPRESSION-ANXIETY-STRESS IN IRRITABLE BOWEL SYNDROME PATIENTS. |
| Q37907937 | Abdominal bloating and distension: what is the role of the microbiota. |
| Q45127551 | Abdominal pain and the neurotrophic system in ulcerative colitis. |
| Q37811371 | Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms |
| Q39359526 | Abdominal pain-related functional gastrointestinal disorders in children |
| Q39177157 | Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients. |
| Q89848667 | Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation |
| Q51337691 | Acute experimental stress evokes a differential gender-determined increase in human intestinal macromolecular permeability. |
| Q40094708 | Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period. |
| Q36421071 | Alcohol Use Disorder Increases the Risk of Irritable Bowel Disease: A Nationwide Retrospective Cohort Study |
| Q43171523 | Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective |
| Q35042476 | Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome |
| Q34882053 | Alteration of fecal microbiota in patients with postinfectious irritable bowel syndrome |
| Q34586306 | Alterations in the colonic microbiota in response to osmotic diarrhea |
| Q36312370 | Altered colorectal afferent function associated with TNBS-induced visceral hypersensitivity in mice |
| Q35429853 | Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet |
| Q35529596 | Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. |
| Q36240095 | Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome |
| Q24630575 | An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome |
| Q35811471 | Anti-Inflammatory Activities of a Chinese Herbal Formula IBS-20 In Vitro and In Vivo. |
| Q35885941 | Anti-enteric Neuronal Antibodies and the Irritable Bowel Syndrome: Are They Really the Accused? |
| Q36933771 | Anticipation of thermal pain in diverticular disease. |
| Q35111263 | Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? |
| Q35044211 | Bacterial infections in childhood: A risk factor for gastrointestinal and other diseases? |
| Q40163181 | Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products |
| Q51706674 | Bowel disorders. |
| Q27024801 | Brain-gut axis: from basic understanding to treatment of IBS and related disorders |
| Q35597520 | Brain-gut-microbe communication in health and disease |
| Q40039181 | Campylobacter: from microbiology to prevention |
| Q33805934 | Can fecal microbiota transplantation cure irritable bowel syndrome? |
| Q48306528 | Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management |
| Q38343940 | Centrally targeted pharmacotherapy for chronic abdominal pain |
| Q34409219 | Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders. |
| Q35001118 | Changes in the symptom pattern and the densities of large-intestinal endocrine cells following Campylobacter infection in irritable bowel syndrome: a case report |
| Q35590592 | Changes of cytokine levels in a mouse model of post-infectious irritable bowel syndrome |
| Q38093431 | Chronic diarrhea in travelers |
| Q38192977 | Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia |
| Q38003044 | Chronic gastrointestinal consequences of acute infectious diarrhea: evolving concepts in epidemiology and pathogenesis |
| Q54522312 | Chronic stress mediators act synergistically on colonic nociceptive mouse dorsal root ganglia neurons to increase excitability. |
| Q55312184 | Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. |
| Q45389087 | Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. |
| Q83506915 | Clinical pearls in infectious diseases |
| Q35095269 | Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome |
| Q47559834 | Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum? |
| Q35183955 | Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon |
| Q46258357 | Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons |
| Q38155671 | Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women |
| Q91653525 | Confocal laser endomicroscopy detects colonic inflammation in patients with irritable bowel syndrome: a prospective study |
| Q33958801 | Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome |
| Q35809342 | Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications |
| Q38804714 | Corticotropin-releasing factor augments LPS-induced immune/inflammatory responses in JAWSII cells |
| Q38275041 | Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. |
| Q52673108 | Current insights into the innate immune system dysfunction in irritable bowel syndrome. |
| Q35772245 | Cytokine Response after Stimulation with Key Commensal Bacteria Differ in Post-Infectious Irritable Bowel Syndrome (PI-IBS) Patients Compared to Healthy Controls |
| Q37796599 | Diagnosis and management of IBS. |
| Q33649131 | Diarrhoea in a large prospective cohort of European travellers to resource-limited destinations |
| Q51530376 | Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults. |
| Q96303859 | Differences in efficacy and safety of lubiprostone used for idiopathic vs opioid-induced constipation: meta-analysis of East Asian and Western populations |
| Q48864958 | Disease burden of post-infectious irritable bowel syndrome in The Netherlands |
| Q34432365 | Duodenal administered seal oil for patients with subjective food hypersensitivity: an explorative open pilot study |
| Q26751421 | Early life programming of pain: focus on neuroimmune to endocrine communication |
| Q54998518 | Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. |
| Q47825106 | Effect of Lactobacillus rhamnosus GG supernatant on serotonin transporter expression in rats with post-infectious irritable bowel syndrome. |
| Q34129435 | Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome |
| Q90136095 | Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome |
| Q92829487 | Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome |
| Q84078756 | Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat |
| Q28069204 | Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases |
| Q36552765 | Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial |
| Q36454329 | Enhanced excitability of guinea pig inferior mesenteric ganglion neurons during and following recovery from chemical colitis |
| Q38838568 | Enteric Neuronal Regulation of Intestinal Inflammation |
| Q64883765 | Enteric nervous system development: what could possibly go wrong? |
| Q64244148 | Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial |
| Q45332660 | Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review |
| Q27002867 | Epigenetics and chromatin dynamics: a review and a paradigm for functional disorders |
| Q35513973 | Evidence-based clinical practice guidelines for irritable bowel syndrome. |
| Q52603772 | Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders. |
| Q58566946 | Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity |
| Q37533007 | Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting |
| Q35059823 | Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome |
| Q100727431 | Food protein-induced allergic proctocolitis in infants: Literature review and proposal of a management protocol |
| Q34298260 | From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. |
| Q35773802 | Functional bowel disorders in adults |
| Q61798328 | Functional gastrointestinal disorders and gut-brain axis: What does the future hold? |
| Q57154765 | Gastro 2013 APDW/WCOG Shanghai working party report: chronic diarrhea: definition, classification, diagnosis |
| Q41267128 | Gastroesophageal reflux symptoms not responding to proton pump inhibitor: GERD, NERD, NARD, esophageal hypersensitivity or dyspepsia? |
| Q33818667 | Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome |
| Q37858651 | Gene, environment, and brain-gut interactions in irritable bowel syndrome |
| Q38782466 | Gene-environment interactions and the enteric nervous system: Neural plasticity and Hirschsprung disease prevention |
| Q38119270 | Genes and functional GI disorders: from casual to causal relationship. |
| Q36262834 | Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome |
| Q28396111 | Global Epidemiology of Campylobacter Infection |
| Q91971454 | Global burden of irritable bowel syndrome: trends, predictions and risk factors |
| Q29616812 | Gut Microbiota in Health and Disease |
| Q37791942 | Gut microbiota and related diseases: clinical features |
| Q26768550 | Gut microbiota role in irritable bowel syndrome: New therapeutic strategies |
| Q40831313 | Gut-derived cholecystokinin contributes to visceral hypersensitivity via nerve growth factor-dependent neurite outgrowth |
| Q55190074 | Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response. |
| Q36395349 | High densities of serotonin and peptide YY cells in the colon of patients with lymphocytic colitis |
| Q40604510 | High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection |
| Q36144375 | IBS and IBD - separate entities or on a spectrum? |
| Q35102935 | IBS with intestinal microbial dysbiosis: a new and clinically relevant subgroup? |
| Q39319686 | IL-13-mediated immunological control of enterochromaffin cell hyperplasia and serotonin production in the gut. |
| Q39445579 | INTESTINAL MICROBIOTA IN DIGESTIVE DISEASES. |
| Q45169761 | Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. |
| Q34346102 | Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome |
| Q38104610 | Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? |
| Q36133221 | Immunoinflammation and functional gastrointestinal disorders |
| Q28086910 | Immunomodulation of enteric neural function in irritable bowel syndrome |
| Q57153930 | Immunopathological and molecular basis of functional dyspepsia and current therapeutic approaches |
| Q34444343 | Immunophenotyping in post-giardiasis functional gastrointestinal disease and chronic fatigue syndrome |
| Q41726271 | Incidence and predictive factors of irritable bowel syndrome after acute diverticulitis in Korea |
| Q38234198 | Infectious diarrhea: an overview |
| Q36451342 | Intestinal commensal microbes as immune modulators |
| Q33577262 | Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon? |
| Q57463602 | Intestinal hyperpermeability: a gateway to multi-organ failure? |
| Q38098478 | Intestinal microbiota and its role in irritable bowel syndrome (IBS). |
| Q24631357 | Intestinal microbiota in functional bowel disorders: a Rome foundation report |
| Q33958729 | Intestinal microbiota in pathophysiology and management of irritable bowel syndrome |
| Q38014500 | Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. |
| Q26853285 | Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea |
| Q38447499 | Investigation of interleukin-10 promoter polymorphisms and interleukin-10 levels in children with irritable bowel syndrome. |
| Q48389586 | Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches |
| Q36207200 | Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications |
| Q58701391 | Irritable bowel syndrome |
| Q35502339 | Irritable bowel syndrome - An inflammatory disease involving mast cells |
| Q38568623 | Irritable bowel syndrome among a cohort of European travelers to resource-limited destinations |
| Q35810402 | Irritable bowel syndrome and gastrointestinal parasite infection in a developing nation environment |
| Q40174714 | Irritable bowel syndrome in middle-aged and elderly Palestinians: its prevalence and effect of location of residence. |
| Q35581343 | Irritable bowel syndrome--the main recommendations |
| Q36310403 | Irritable bowel syndrome: diagnosis and pathogenesis |
| Q37898417 | Irritable bowel syndrome: gender, infection, lifestyle or what else? |
| Q46180365 | Irritable bowel syndrome: is the colonic mucosa to blame? |
| Q26860280 | Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome |
| Q35994064 | Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. |
| Q33735229 | Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine |
| Q38192048 | Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment |
| Q92994462 | Is fecal calprotectin always normal in children with irritable bowel syndrome? |
| Q35450209 | Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? |
| Q38191561 | Is irritable bowel syndrome an organic disorder? |
| Q39009387 | Is irritable bowel syndrome associated with chronic hepatitis C? |
| Q36036768 | JCM-16021, a Chinese Herbal Formula, Attenuated Visceral Hyperalgesia in TNBS-Induced Postinflammatory Irritable Bowel Syndrome through Reducing Colonic EC Cell Hyperplasia and Serotonin Availability in Rats |
| Q36347301 | Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome |
| Q26782227 | Lactose Intolerance in Adults: Biological Mechanism and Dietary Management |
| Q37303691 | Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. |
| Q59297393 | Long-Term Consequences of Cryptosporidium and Giardia Gastroenteritis |
| Q37058979 | Long-term Clinical Course of Post-infectious Irritable Bowel Syndrome After Shigellosis: A 10-year Follow-up Study |
| Q38233620 | Management of chronic Giardia infection |
| Q38121998 | Management of irritable bowel syndrome with constipation: a flexible approach to treating a complex condition with multiple symptoms |
| Q28385300 | Management of the returning traveler with diarrhea |
| Q86948168 | Managing irritable bowel syndrome |
| Q35430640 | Mast Cell-dependent Mesenteric Afferent Activation by Mucosal Supernatant From Different Bowel Segments of Guinea Pigs With Post-infectious Irritable Bowel Syndrome. |
| Q84742904 | Mast cells |
| Q37871421 | Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome |
| Q98386872 | Microbial dysbiosis in irritable bowel syndrome: A single-center metagenomic study in Saudi Arabia |
| Q35825753 | Microbial signatures in post-infectious irritable bowel syndrome--toward patient stratification for improved diagnostics and treatment |
| Q43323785 | Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome. |
| Q44169460 | Morbidity among Israeli paediatric travellers |
| Q36539600 | Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS) |
| Q38810529 | Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome. |
| Q35061903 | Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome |
| Q91942688 | Neuro-Immune Networks in Gastrointestinal Disorders |
| Q38191576 | Neuroanatomy of lower gastrointestinal pain disorders |
| Q36451817 | Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. |
| Q38227089 | Neuroplasticity and dysfunction after gastrointestinal inflammation |
| Q38601834 | New and Investigational Agents for Irritable Bowel Syndrome |
| Q83284775 | New insights into the impact of the intestinal microbiota on health and disease: a symposium report |
| Q42695148 | New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond |
| Q38059436 | New treatments for IBS. |
| Q36219973 | Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders |
| Q38179528 | On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens |
| Q35464242 | P2X3 receptors mediate visceral hypersensitivity during acute chemically-induced colitis and in the post-inflammatory phase via different mechanisms of sensitization |
| Q34627613 | Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness |
| Q34094755 | Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions |
| Q37677017 | Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis. |
| Q26775596 | Pathogenic Microorganisms and Pancreatic Cancer |
| Q35730488 | Pathophysiologic findings of irritable bowel syndrome in china |
| Q27004352 | Persistent digestive disorders in the tropics: causative infectious pathogens and reference diagnostic tests |
| Q37153280 | Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice |
| Q34176708 | Pharmacokinetics of two alkaloids after oral administration of rhizoma coptidis extract in normal rats and irritable bowel syndrome rats |
| Q92949791 | Phenotypic features of patients with post-infectious irritable bowel syndrome |
| Q57063253 | Post-infectious IBS: Defining its clinical features and prognosis using an internet-based survey |
| Q92406298 | Post-infectious Irritable Bowel Syndrome: A Narrative Review |
| Q36697730 | Post-infectious and non post-infectious irritable bowel syndrome: A comparative study |
| Q34415870 | Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection |
| Q37858647 | Post-infectious irritable bowel syndrome: the past, the present and the future |
| Q39587155 | Postinfectious and sporadic functional gastrointestinal disorders have different prevalences and rates of overlap: results from a controlled cohort study 3 years after acute giardiasis |
| Q39441319 | Postinfectious irritable bowel syndrome after travelers' diarrhea--a cohort study |
| Q34696026 | Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: a large cross-sectional study |
| Q41087764 | Preinduction of heat shock protein 70 protects mice against post-infection irritable bowel syndrome via NF-κB and NOS/NO signaling pathways |
| Q39077262 | Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis |
| Q43310368 | Prevalence, incidence, and risk factors of intestinal parasites in Danish primary care patients with irritable bowel syndrome |
| Q36567134 | Probiotics and the gut microbiota in intestinal health and disease |
| Q64905677 | Prolonged Duodenal Mucosal Lymphocyte Alterations in Patients With and Without Postinfectious Functional Gastrointestinal Disorders After Giardia Infection. |
| Q42086945 | Protective effect of huoxiang zhengqi oral liquid on intestinal mucosal mechanical barrier of rats with postinfectious irritable bowel syndrome induced by acetic Acid |
| Q47150181 | Protozoan parasites in irritable bowel syndrome: A case-control study |
| Q42223268 | Psychometric scores and persistence of irritable bowel after Campylobacter concisus infection |
| Q33764582 | RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study |
| Q36475502 | Randomised controlled trial of mesalazine in IBS. |
| Q35035294 | Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects |
| Q45707638 | Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. |
| Q38548795 | Relationship between infectious gastroenteritis and irritable bowel syndrome |
| Q37324440 | Repeated Water Avoidance Stress Alters Mucosal Mast Cell Counts, Interleukin-1β Levels with Sex Differences in the Distal Colon of Wistar Rats |
| Q35627347 | Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia |
| Q92307557 | Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome |
| Q33959307 | Review article: new receptor targets for medical therapy in irritable bowel syndrome |
| Q33466527 | Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? |
| Q26772962 | Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials |
| Q38340085 | Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. |
| Q37976477 | Rifaximin for the treatment of irritable bowel syndrome |
| Q55527145 | Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. |
| Q26777544 | Role of environmental pollution in irritable bowel syndrome |
| Q37715205 | Role of gut pathogens in development of irritable bowel syndrome |
| Q56366234 | Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome |
| Q92053503 | Second Asian Consensus on Irritable Bowel Syndrome |
| Q42509169 | Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes |
| Q33987389 | Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. |
| Q35815638 | Serum and colonic mucosal immune markers in irritable bowel syndrome |
| Q34423283 | Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy |
| Q92723060 | Sex Differences in Gut Microbiota |
| Q34575108 | Sex difference in irritable bowel syndrome: do gonadal hormones play a role? |
| Q37629667 | Sex hormones in the modulation of irritable bowel syndrome |
| Q39303889 | Sex-Related Differences in GI Disorders |
| Q24262889 | Small intestinal bacterial overgrowth syndrome |
| Q84912194 | Soluble mediators released from PI-IBS patients' colon induced alteration of mast cell: involvement of reactive oxygen species |
| Q27322790 | Spatial Localization and Binding of the Probiotic Lactobacillus farciminis to the Rat Intestinal Mucosa: Influence of Chronic Stress |
| Q36811745 | Stress and gene expression of individuals with chronic abdominal pain |
| Q30459512 | Stress and visceral pain: from animal models to clinical therapies |
| Q35087100 | Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities |
| Q35161361 | Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study |
| Q34231605 | Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors |
| Q46147064 | Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. |
| Q37789650 | Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome |
| Q38420105 | Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea |
| Q37280260 | The Brain-Gut Axis in Abdominal Pain Syndromes |
| Q37694194 | The Effect of Tong-Xie-Yao-Fang on Intestinal Mucosal Mast Cells in Postinfectious Irritable Bowel Syndrome Rats |
| Q85064011 | The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population |
| Q48504199 | The Risk of Chronic Gastrointestinal Disorders Following Acute Infection with Intestinal Parasites |
| Q28540843 | The analysis of factors associated with progression of isolated terminal ileal lesions |
| Q33724754 | The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. |
| Q40069003 | The chemical coding of 5-hydroxytryptamine containing enteroendocrine cells in the mouse gastrointestinal tract. |
| Q38032174 | The chronic gastrointestinal consequences associated with campylobacter |
| Q34624014 | The clinical importance of intestinal microbiota |
| Q37490692 | The duration of gastrointestinal and joint symptoms after a large waterborne outbreak of gastroenteritis in Finland in 2007--a questionnaire-based 15-month follow-up study |
| Q51123173 | The effect of chemically induced colitis, psychological stress and their combination on visceral pain in female Wistar rats. |
| Q34041082 | The first 1000 cultured species of the human gastrointestinal microbiota. |
| Q35587508 | The immune system in irritable bowel syndrome |
| Q35006863 | The inhibitory effect of tongxieyaofang on rats with post infectious irritable bowel syndrome through regulating colonic par-2 receptor |
| Q37918323 | The intestinal microbiota and chronic disorders of the gut. |
| Q54319433 | The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. |
| Q35838055 | The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. |
| Q59807725 | The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation |
| Q35054658 | The microbiome: stress, health and disease |
| Q36392101 | The microbiota link to irritable bowel syndrome: an emerging story |
| Q26830491 | The relationship between intestinal parasites and some immune-mediated intestinal conditions |
| Q35658695 | The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection |
| Q37873352 | The role of eosinophils and mast cells in intestinal functional disease. |
| Q27001546 | The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials |
| Q27014922 | The role of the gut microbiome in the pathogenesis and treatment of obesity |
| Q40830748 | The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission |
| Q39562120 | The timing and location of glial cell line-derived neurotrophic factor expression determine enteric nervous system structure and function. |
| Q36998938 | The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome |
| Q28749706 | Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome |
| Q26798003 | Towards a systems view of IBS |
| Q46410539 | Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. |
| Q42961151 | Treatment of irritable bowel syndrome with probiotics: growing evidence |
| Q33745764 | Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. |
| Q27004645 | Unraveling the ties between irritable bowel syndrome and intestinal microbiota |
| Q92708476 | Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management |
| Q27002380 | Upper gastrointestinal microbiota and digestive diseases |
| Q24658463 | Visceral hypersensitive rats share common dysbiosis features with irritable bowel syndrome patients |
| Q47124809 | Wuji Wan Formula Ameliorates Diarrhea and Disordered Colonic Motility in Post-inflammation Irritable Bowel Syndrome Rats by Modulating the Gut Microbiota |
| Q54705452 | [Functional gastrointestinal diseases]. |
| Q84275596 | [Post-infectious functional gastrointestinal disorders: from the acute episode to chronicity] |
| Q50503161 | [Psychobiological mechanisms in the pathophysiology of chronic visceral pain]. |
Search more.